Featured Research

from universities, journals, and other organizations

New NA Inhibitor Offers Long-Lasting Protection Against Influenza Virus

Date:
January 29, 2009
Source:
American Society for Microbiology
Summary:
A recent study suggests that a derivative of a new potent neuraminidase (NA) inhibitor offers long-lasting protection against various strains of influenza viruses A and B, including the avian influenza subtype N1 and current drug-resistant strains.

A recent study suggests that a derivative of a new potent neuraminidase (NA) inhibitor offers long-lasting protection against various strains of influenza viruses A and B, including the avian influenza subtype N1 and current drug-resistant strains. The researchers from Daiichi Sankyo Co. Ltd., Tokyo, Japan report their findings in the journal Antimicrobial Agents and Chemotherapy.

Related Articles


Influenza is a serious respiratory illness caused by influenza A and B viruses and is highly contagious among humans. Approximately 3.5 million cases of severe illness and between 300,000 and 500,000 deaths are attributed to influenza outbreaks each year. Current antiviral drugs available include two NA inhibitors zanamivir and oseltamivir, both of which require twice-daily administration. In addition, oseltamivir (the predominant choice for treatment) has reached such high levels of circulation that drug-resistant mutations are emerging emphasizing the need for a new potent and lasting treatment option.

NA inhibitors bind to the NA surface protein of new virus particles and prevent their release from the host cell. In the study the newly identified NA inhibitor R-125489 inhibited the NA activities of various influenza type A and B viruses, including subtypes N1 to N9 and oseltamivir-resistant strains. When administered intranasally to mice, the survival rate of R-125489 was similar to that of zanamivir. Further, when compared to R-125489 and zanamivir in the same mouse model, a concentrated form of R-125489, now identified as CS-8958 resulted in a prolonged survival rate after a single dose even when administered 7 days before infection.

"It is suggested that intranasally administered CS-8958 works as a long-acting NA inhibitor and shows in vitro efficacy as a result of a single intranasal administration," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yamashita et al. CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity. Antimicrobial Agents and Chemotherapy, 2008; 53 (1): 186 DOI: 10.1128/AAC.00333-08

Cite This Page:

American Society for Microbiology. "New NA Inhibitor Offers Long-Lasting Protection Against Influenza Virus." ScienceDaily. ScienceDaily, 29 January 2009. <www.sciencedaily.com/releases/2009/01/090127093114.htm>.
American Society for Microbiology. (2009, January 29). New NA Inhibitor Offers Long-Lasting Protection Against Influenza Virus. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2009/01/090127093114.htm
American Society for Microbiology. "New NA Inhibitor Offers Long-Lasting Protection Against Influenza Virus." ScienceDaily. www.sciencedaily.com/releases/2009/01/090127093114.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins